Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell E Lewis

Showing results (71-80 of 225) with videos related to

Pageof 23
Sort By:
Pharmacotherapy|September 17, 2005
Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapyMichail S Lionakis, Russell E Lewis, Georgios Chamilos, et al.
The Journal of Infection|September 7, 2007
Random plasma concentrations of voriconazole decline over timeVictor Mulanovich, Russell E Lewis, Issam I Raad, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2006
Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed miceRussell E Lewis, Georgios Chamilos, Randall A Prince, et al.
Microbiology and Immunology|February 9, 2018
Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosaVincent H Tam, Cynthia Pérez, Kimberly R Ledesma, et al.
The Lancet. Infectious Diseases|December 22, 2006
Role of mini-host models in the study of medically important fungiGeorgios Chamilos, Michail S Lionakis, Russell E Lewis, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosisRussell E Lewis, Randall A Prince, Jingduan Chi, et al.
The Journal of Infectious Diseases|January 15, 2008
Virulence studies of Scedosporium and Fusarium species in Drosophila melanogasterGregory A Lamaris, Georgios Chamilos, Russell E Lewis, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 7, 2026
In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolatesGiulia Zocche, Russell E Lewis, Gabriele Bianco, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral SuspensionRussell E Lewis, Dimitrios P Kontoyiannis, Pierluigi Viale, et al.
Blood|October 22, 2009
Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolitesRonen Ben-Ami, Russell E Lewis, Konstantinos Leventakos, et al.
Pageof 23

Showing results (71-80 of 225) with videos related to

Sort By:
Pageof 23
Pharmacotherapy|September 17, 2005
Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapyMichail S Lionakis, Russell E Lewis, Georgios Chamilos, et al.
The Journal of Infection|September 7, 2007
Random plasma concentrations of voriconazole decline over timeVictor Mulanovich, Russell E Lewis, Issam I Raad, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2006
Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed miceRussell E Lewis, Georgios Chamilos, Randall A Prince, et al.
Microbiology and Immunology|February 9, 2018
Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosaVincent H Tam, Cynthia Pérez, Kimberly R Ledesma, et al.
The Lancet. Infectious Diseases|December 22, 2006
Role of mini-host models in the study of medically important fungiGeorgios Chamilos, Michail S Lionakis, Russell E Lewis, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2002
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosisRussell E Lewis, Randall A Prince, Jingduan Chi, et al.
The Journal of Infectious Diseases|January 15, 2008
Virulence studies of Scedosporium and Fusarium species in Drosophila melanogasterGregory A Lamaris, Georgios Chamilos, Russell E Lewis, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 7, 2026
In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolatesGiulia Zocche, Russell E Lewis, Gabriele Bianco, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral SuspensionRussell E Lewis, Dimitrios P Kontoyiannis, Pierluigi Viale, et al.
Blood|October 22, 2009
Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolitesRonen Ben-Ami, Russell E Lewis, Konstantinos Leventakos, et al.
Pageof 23